Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ELIXICON vs ELIXOMIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline is a xanthine derivative that inhibits phosphodiesterase, leading to increased intracellular cyclic AMP levels. It also acts as a nonselective adenosine receptor antagonist, resulting in bronchodilation and anti-inflammatory effects.
ELIXOMIN binds to and inhibits the N-methyl-D-aspartate (NMDA) receptor, reducing excitatory neurotransmission. It also modulates gamma-aminobutyric acid (GABA) activity, enhancing inhibitory signaling.
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma,Management of chronic obstructive pulmonary disease (COPD),Off-label: Apnea of prematurity
Treatment of refractory epilepsy,Adjunctive therapy for complex partial seizures,Off-label: neuropathic pain management,Off-label: bipolar disorder maintenance
400 mg orally every 6 hours or 600 mg orally every 8 hours; extended-release: 600-1200 mg orally every 12 hours.
500 mg orally once daily with a full glass of water, regardless of meals.
Terminal elimination half-life: 4-6 hours in adults; 3-4 hours in children; prolonged in hepatic impairment or congestive heart failure. Context: dosing interval adjustment required in these conditions.
Terminal elimination half-life is 12-15 hours in adults with normal renal function; extends to 24-36 hours in moderate renal impairment (Cr Cl 30-50 m L/min).
Primarily hepatic metabolism via cytochrome P450 1A2 (CYP1A2). Minor pathways include CYP2E1 and CYP3A4. Metabolites are excreted renally.
Primarily metabolized by CYP3A4 and CYP2C19 isoenzymes; undergoes glucuronidation via UGT1A4. Active metabolite: N-desethyl-ELIXOMIN.
Renal: 50% unchanged; hepatic metabolism to 3-methylxanthine, theophylline, etc. Biliary/fecal: minimal.
Renal elimination of unchanged drug accounts for 60-70% of clearance; biliary/fecal excretion accounts for 20-25%; the remainder is metabolized hepatically with inactive metabolites excreted renally.
Approximately 40% bound, primarily to albumin.
98% bound to albumin and alpha-1-acid glycoprotein.
Vd: 0.3-0.5 L/kg; indicates distribution into total body water, minimal tissue binding.
0.6-0.8 L/kg; distributes rapidly into total body water, with moderate tissue binding.
Oral immediate-release: 100%; Extended-release: 100% (well-absorbed, no first-pass metabolism).
Oral: 70-80% (due to first-pass metabolism); Intramuscular: 90-95%.
GFR > 50 m L/min: no adjustment; GFR 10-50 m L/min: reduce dose by 25-50% and monitor theophylline levels; GFR < 10 m L/min: reduce dose by 50% and monitor levels.
GFR > 60 m L/min: no adjustment; GFR 30-60 m L/min: 250 mg once daily; GFR 15-29 m L/min: 125 mg once daily; GFR < 15 m L/min or dialysis: not recommended.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: reduce dose by 75% and monitor levels.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% (250 mg once daily); Class C: not recommended.
Initial: 5 mg/kg/dose orally every 6 hours; maintenance: 100-400 mg/day in divided doses; monitor levels aggressively.
Weight ≥ 40 kg: 500 mg once daily; Weight 20-39 kg: 250 mg once daily; Weight < 20 kg: not established.
Start at lowest effective dose (e.g., 200 mg orally every 12 hours) due to reduced clearance; monitor theophylline levels and adjust based on response and tolerability.
No specific dose adjustment except based on renal function. Monitor for increased risk of QT prolongation and electrolyte disturbances. Initial dose should be 250 mg once daily if Cr Cl < 60 m L/min.
Theophylline has a narrow therapeutic index; plasma levels should be monitored to avoid toxicity. Dosage should be individualized based on steady-state serum concentrations. Concurrent illness, fever, or changes in smoking habits can alter theophylline clearance.
WARNING: Risk of suicidal thoughts and behaviors; monitor for worsening depression or emergence of suicidal ideation.
Risk of seizures at high serum levels; may induce or worsen arrhythmias; use with caution in patients with peptic ulcer disease, hyperthyroidism, or seizure disorders; drug interactions with cimetidine, fluoroquinolones, macrolides, and allopurinol can increase theophylline levels.
Hepatotoxicity (monitor LFTs); hematologic effects (thrombocytopenia, neutropenia); severe dermatologic reactions (SJS/TEN); pancreatitis; hyperammonemia; somnolence and dizziness; withdrawal seizures upon abrupt discontinuation.
Hypersensitivity to theophylline or any component of the formulation; pre-existing cardiac arrhythmias (e.g., tachyarrhythmias); active seizure disorder.
Absolute: Hypersensitivity to ELIXOMIN or any component; history of drug-induced liver injury; concomitant use with MAOIs. Relative: Hepatic impairment; renal insufficiency (Cr Cl <30 m L/min); pregnancy (teratogenic effects in animal studies).
Avoid large amounts of caffeine-containing foods and beverages such as coffee, tea, cola, and chocolate as they may increase side effects like jitteriness and insomnia. High-fat meals may affect absorption; take consistently with respect to meals. Charcoal-broiled foods may increase metabolism of theophylline, reducing efficacy.
Grapefruit and grapefruit juice significantly increase ELIXOMIN plasma concentrations, increasing risk of toxicity. High-potassium foods (e.g., bananas, oranges, spinach) should be limited due to risk of hyperkalemia.
Insufficient human data; animal studies show fetal toxicity at high doses. Avoid in first trimester unless benefit outweighs risk. Second and third trimester: use only if clearly needed.
ELIXOMIN is contraindicated in pregnancy (Category X). First trimester: High risk of major congenital malformations including neural tube defects, cardiovascular anomalies. Second and third trimesters: Increased risk of spontaneous abortion, preterm delivery, and fetal growth restriction due to uteroplacental insufficiency.
Excreted into breast milk; M/P ratio unknown. Caution advised, monitor infant for adverse effects.
Not recommended during breastfeeding. Excreted in human milk; M/P ratio not established. Potential for serious adverse reactions in nursing infant (e.g., nephrotoxicity, ototoxicity).
Increased clearance during pregnancy may require dose adjustment; monitor therapeutic levels.
Due to increased glomerular filtration rate (GFR) in pregnancy, higher doses of ELIXOMIN may be required to achieve therapeutic drug levels. However, given teratogenicity, use is contraindicated; alternative therapy should be considered.
ELIXICON (theophylline) requires therapeutic drug monitoring due to narrow therapeutic index of 10-20 mcg/m L. Avoid in patients with active peptic ulcer disease or seizure disorders. Use with caution in heart failure, liver disease, and elderly patients due to reduced clearance. Cigarette smoking induces metabolism, requiring dose adjustments. Common side effects include nausea, vomiting, and insomnia; toxicity presents with tachycardia, seizures, or ventricular arrhythmias.
Monitor serum potassium levels closely; ELIXOMIN can cause life-threatening hyperkalemia especially in patients with renal impairment. Avoid concurrent use with potassium-sparing diuretics.
Take exactly as prescribed and do not change dose without consulting your doctor.,Avoid smoking and second-hand smoke as it affects how the medication works.,Limit caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects.,Report symptoms of toxicity: persistent nausea, vomiting, rapid heart rate, or seizures.,Do not take this medication with other cold or asthma remedies without medical advice.
Do not consume grapefruit or grapefruit juice while taking ELIXOMIN.,Take with food to reduce gastrointestinal upset.,Report any muscle cramps, palpitations, or irregular heartbeat immediately.,Avoid potassium supplements and salt substitutes containing potassium.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ELIXICON vs ELIXOMIN, answered by our medical review team.
ELIXICON is a Xanthine Bronchodilator that works by Theophylline is a xanthine derivative that inhibits phosphodiesterase, leading to increased intracellular cyclic AMP levels. It also acts as a nonselective adenosine receptor antagonist, resulting in bronchodilation and anti-inflammatory effects.. ELIXOMIN is a Xanthine Bronchodilator that works by ELIXOMIN binds to and inhibits the N-methyl-D-aspartate (NMDA) receptor, reducing excitatory neurotransmission. It also modulates gamma-aminobutyric acid (GABA) activity, enhancing inhibitory signaling.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ELIXICON and ELIXOMIN depend on the specific clinical indication. These are both Xanthine Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ELIXICON is: 400 mg orally every 6 hours or 600 mg orally every 8 hours; extended-release: 600-1200 mg orally every 12 hours.. The standard adult dose of ELIXOMIN is: 500 mg orally once daily with a full glass of water, regardless of meals.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ELIXICON and ELIXOMIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ELIXICON is classified as Category C. Insufficient human data; animal studies show fetal toxicity at high doses. Avoid in first trimester unless benefit outweighs risk. Second and third trimester: use only if clearly n. ELIXOMIN is classified as Category C. ELIXOMIN is contraindicated in pregnancy (Category X). First trimester: High risk of major congenital malformations including neural tube defects, cardiovascular anomalies. Second . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.